Rosemarie L. Fisher

This study was performed to examine the relationships between portal pressure measurements and the presence of esophagogastric varices, the size of varices and the occurrence of hemorrhage from varices in 93 patients with alcoholic cirrhosis, using standardized measurements of portal pressure by hepatic vein catheterization. The mean hepatic vein pressure gradient (HVPG) was significantly higher in 49 patients who had bled from varices than in 44 cirrhotic patients who had not (20.4 ± 5.1 vs. 16.0 ° 5. 2; p < 0.001). None of the 49 patients who had bled from varices had an HVPG <12 mm Hg. Among the 87 patients who had been examined by endoscopy for varices, all 72 with varices had an HVPG > 12 mm Hg. Six of 15 cirrhotic patients without varices had HVPG < 12 mm Hg. The mean HVPG in the 15 patients without varices (15.1 ± 6.8 mm Hg) was lower than the 72 patients with varices (19.3 ± 4.8 mm Hg; p < 0.01). Of the 72 patients with varices, 40 had large varices, 28 had small varices, and in four patients variceal size coukt not be assessed adequately. The mean HVPG was similar in the patients with large or small varices (19.8 ± 4.8 vs. 18.3 ± 5.0 mm Hg; p < 0.10). There was a positive relationship between the presence of large varices and the occurrence of bleeding from varices. Thirty–three of the 46 patients who had bled from varices had large varices (72%) compared to 7 of the 22 who had not bled from varices (32%) (p < 0.01). The mean HVPG was similar in groups with large varices who had bled (20.3 ± 4.9) and in the group with small varices who had bled (20.2 ± 6.2 mm Hg) (p > 0.10). The mean HVPG in the groups of patients with large varices who had not bled was similar to those with small varices who had not bled (17.3 ± 3.1 vs. 16.7 ± 3.2 mm Hg) (p > 0.10). In both groups, the pressure was lower in those who had not bled. We confirm previous observations that an HVPG > 12 mm Hg is necessary for the occurrence of variceal hemorrhage. We note in addition that this pressure gradient is necessary for the appearance of gastroesophageal varices. Elevated portal pressure plays a major role in the development of esophageal varices, but other factors contribute to the precipitation of hemorrhage from varices. All of these factors, which include size of the varix, thickness of the wall and transmural pressure are integrated in the wall stress formula, which is based on the LaPlace formula. Risk factors are multiple and variable and may interact in the individual patient to precipitate variceal hemorrhage.

To assess the effectiveness of propranolol in the prevention of initial variceal hemorrhage, a double-blind, randomized trial was carried out in three centers. Patients with cirrhosis (78% alcoholic), hepatic venous pressure gradients greater than 12 mm Hg and endoscopically proven esophageal varices were randomly assigned to propranolol (51 patients) or placebo (51 patients). Of the 102 patients, 58% were Child's class A, 34% were Child's class B and 8% were Child's class C. Daily dosage was determined by the administration of progressively increasing doses of propranolol with the hepatic vein catheter in place to achieve a 25% decrease in hepatic venous pressure gradient, a decrease in hepatic venous pressure gradient to less than 12 mm Hg or a decrease in resting heart rate to less than 55 beats/min. During a mean follow-up period of 16.3 mo, 11 patients in the placebo group (22%) bled from esophageal varices compared with 2 in the propranolol group (4%) during a mean period of 17.1 mo (p less than 0.01). Three additional patients (6%) in the placebo group bled from portal hypertensive gastropathy compared with none in the propranolol group. Propranolol appeared effective in preventing bleeding from large varices. Eleven deaths (22%) occurred in the placebo group compared with eight deaths (16%) in the propranolol group (NS). The mean dose of propranolol was 132 mg/day, and the median dose was 80 mg/day. Using a compliance index (pill count, clinic attendance, alcohol and propranolol levels and alcohol history), 81% of the propranolol patients and 77% of the placebo patients were considered compliant. Complications severe enough to require cessation of therapy occurred in eight patients (16%) in the propranolol group and four in the placebo group (8%) (NS). We conclude that propranolol effectively prevents the first variceal hemorrhage in patients with alcoholic cirrhosis and large esophageal varices but does not improve survival.

Between 1975 and 1983, 303 cirrhotic patients with endoscopically proven major variceal hemorrhage were admitted to the participating hospitals of the Boston-New Haven Collaborative Liver Group. Of these, 274 were evaluated for admission to a prospective, randomized controlled trial comparing portal-systemic shunts with distal splenorenal shunts. The criteria for inclusion were as follows: (i) a portohepatic pressure gradient ≥ 12 mmHg; (ii) angiographic evidence of antegrade portal venous flow; (iii) angiographic demonstration that the inferior vena cava and portal, splenic and left renal veins were anatomically suitable for either a portal-systemic or distal splenorenal shunt, and (iv) the patient was a reasonable operative risk. Eighty-one patients from the six participating hospitals fulfilled the criteria and consented to participate. Thirty-eight patients were randomly assigned to have portal-systemic shunt and 43 to have distal splenorenal shunt. After a follow-up period of 11 years (mean = 3.5 years for all patients), survival was found to be similar in the two groups of patients. The 30-day operative mortality was 13% for the portal-systemic shunt group and 9% for the distal splenorenal shunt patients. Late mortality was 55% for the portal-systemic shunt and 37% for the distal splenorenal shunt group. Total mortality was 68% for the portal-systemic shunt and 46% for the distal splenorenal shunt group. None of these differences is statistically significant. In those patients who survived >30 days after surgery, recurrent variceal hemorrhage occurred in four (12%) in the portal-systemic shunt group compared to seven in the distal splenorenal shunt group (18%) (NS). Portal-systemic encephalopathy occurred in 15 (45%) of the operative survivors in the portal-systemic shunt group compared to 20 (51%) in the distal splenorenal shunt group. Severe portal-systemic encephalopathy was observed with equal frequency in the two groups. There was no difference in the time of onset nor the severity of encephalopathy in the two groups. We conclude that the operative mortality and cumulative survival are similar for the two operations and that the frequency and severity of hepatic encephalopathy following distal splenorenal shunt are similar to that after portal-systemic shunt. Based on our observations and previously published data, recurrent hemorrhage from varices appears to be more frequently prevented by portacaval anastomosis than by distal splenorenal shunt.

A sample of 126 patients with cholelithiasis was treated with chenodeoxycholic acid (CDCA) (375 or 750 mg g.d.) for 2 years. Hepatotoxicity was assessed by sequential light (LM) and electron microscopic (EM) analysis of liver biopsies obtained before and after 9 and 24 months of therapy. Patients were without symptoms of biliary colic for 3 months prior to biopsy, less than 70 years old, and had normal tests of liver function. All light microscopy was read blindly by two morphologists, and electron microscopy by one. Only four biopsies (3%) showed severe (3+) abnormalities preventing admission to the study. On evaluation, moderate (2+) LM changes were present in less than 12% of biopsies, while milder changes (1+) were seen more frequently. No severe, dose-related abnormalities were seen in LM over the 2 years of study. However, mild changes (hepatocyte ballooning and lipofuscin, binucleate cells, glycogen nuclei, ductular proliferation, enlarged and fibrotic triads, and sinusoidal congestion) became more prevalent with time (p less than or equal to 0.01) regardless of CDCA dose, according to 1 of the 2 morphologists. Because patients with "proven" cholelithiasis for greater than 2 years (33% of the study population) did not have a greater incidence of morphologic abnormalities than those with the diagnosis for less than 2 years, it is unlikely that these changes were due to the natural history of gallstone disease. Furthermore, electron microscopic findings demonstrated worsening intrahepatic cholestasis and a lesion in two patients which was identical to that produced in animals administered lithocholic acid, the 7-alpha-dehydroxylated metabolite of CDCA. the possibility that clinically significant hepatotoxicity could develop with CDCA therapy greater than 24 months thus cannot be excluded by this study.